Skip to main content

Welcome to our April research update! Getting involved with research is an important way to impact asthma and allergy treatments, education, and awareness.

The Asthma and Allergy Foundation of America (AAFA) works with doctors, researchers, patients, caregivers, public health, and government agencies to conduct and support research that is important to people affected by asthma and allergies.

Here are current research opportunities you can get involved in as a person with asthma or allergies (or as a caregiver for someone with asthma and allergies):

Interviews and Focus Groups

Participants Needed for Adolescent Asthma Self-Management Study

Researchers at Texas Woman’s University want to learn more about adolescent asthma self-management. The researchers would like to understand the experiences and perspectives of adolescents living with asthma. Adolescents will have a chance to speak about their asthma control, asthma tools, and experiences. The study format will be a private interview. Interviews will take place via Zoom.

Who may qualify to participate in this study?

  • Adolescents living with asthma
  • 12-18 years old
  • English speaker


The study participants will be given:

  • $20 Amazon gift card
  • Asthma resources

Participation is voluntary. You can stop the sessions at any time. There is a potential risk for loss of confidentiality in all email downloading, electronic meetings, and internet transactions. If you have further questions about the study, please call Elif Isik (PhD, RN) at (713) 794-2109 or email her at eisik@twu.edu.

LEARN MORE



Asthma and Allergy Clinical Trials

Seeking Volunteers with Asthma for Paid Clinical Trial

Do you or your child have asthma? We are seeking volunteers for a paid, at-home research study that seeks to improve how we treat asthma. The clinical trial will study the effectiveness of a new combination albuterol-budesonide inhaler for the rapid relief of asthma symptoms and daily inflammation.

Sponsored by Science37

LEARN MORE



Potential Participants with Nasal Polyps and Asthma Needed

We are looking for people who have eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) to participate in a clinical research study. CRSwNP is a chronic disease that causes persistent nasal and sinus irritation or swelling. CRSwNP is characterized by nasal growths and high levels of a type of white blood cells, called eosinophils. The purpose of this research is to test the safety and effectiveness of an investigational treatment for people with CRSwNP and asthma who need to improve their disease control further despite previous treatment and surgery. If you are interested in participating, please visit the study website.

Sponsored by IQVIA

LEARN MORE



Latest Asthma and Allergy Research News

Clinical Trial Diversity Craters Out to Lowest Level in 10 Years, IQVIA Finds
Diversity in clinical trial research is important to make sure new treatments are safe and effective for the people who will use them. A new report found that over the past 10 years, fewer Black and Hispanic people have been participating in clinical trials, and representation has never matched national demographics. But the report also showed that clinical trial diversity is better in studies around asthma and allergic conditions than other conditions. Black and Hispanic participation rates are higher than the national demographic rates for allergy and immunology, and Hispanic participation is higher than national rates in respiratory trials. While the diversity in asthma and allergy clinical trials is encouraging, more needs to be done to ensure diversity in clinical trials overall.

Claritin® Takes Aim at Reducing Pollen Levels Through Fruit-, Seed-, and Nut-Bearing Tree Planting Initiative
Many tree species have separate trees that produce pollen and those that produce fruit, seeds, or nuts. In a new initiative, Claritin has launched a new project called DiversiTree™ to help fight rising pollen levels by planting more trees that produce fruit, seeds, or nuts. The project kicked off with tree planting events in two cities ranked by AAFA’s Allergy Capitals™ report as some of the most challenging places to live with allergies - New Orleans, Louisiana, and Richmond, Virginia. The project will also conduct a study to look at the impact of planting low-pollen trees over the next 50 years.

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
The Food and Drug Administration (FDA) is holding an advisory committee meeting on May 11, 2023, to review a new type of medicine for treating allergic reactions, including anaphylaxis. This medicine, called neffy®, is a non-injectable nasal spray for epinephrine. The meeting will give experts the chance to review the medicine and its potential benefits. If approved, neffy could provide a safe and effective option for people who are reluctant to use injectable epinephrine devices.

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 to 3 Years After Receiving Pre-BLA Responses from FDA
DBV Technologies has received feedback from the FDA on their Viaskin Peanut patch. Viaskin Peanut is being tested to treat peanut allergies in children aged 1 to 3 years old with confirmed peanut allergy. The FDA provided positive feedback on the results of the EPITOPE trial but requested another study to continue testing the safety of the patch in young children. The new study will test the patch on 600 kids 1 to 3 years old. They also plan to test how easy the patch is to to use to make sure it is a safe and convenient treatment option.

Allergy Therapeutics Doses First Patients with Peanut Allergy Vaccine
Biotech company Allergy Therapeutics has started testing a new vaccine for peanut allergy, called VLP Peanut. VLP Peanut uses special technology to make the peanut allergen look like a harmless virus to the body's immune system. The medicine is being tested through the PROTECT study. The study will help determine if the vaccine is safe, if people can tolerate it, and if it works to reduce peanut allergies in both healthy and allergic adults. If the medicine works, it could be a new solution for people who are allergic to peanuts.

It is important to stay up to date on news about asthma and allergies. By joining our community and following our blog, you will receive news about research and treatments. Our community also provides an opportunity to connect with other people who manage these conditions for support.

JOIN NOW

Add Comment

Comments (0)

×
×
×
Link copied to your clipboard.
×